Essentials for Clinicians: Head & Neck Cancers - Editors and Contributors

Editors

  • Lisa Licitra, Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan; Università degli Studi Milano, Milan, Italy
  • Michalis V Karamouzis, Molecular Oncology Unit, Department of Biological Chemistry, First Department of Internal Medicine, Laiko Hospital Medical School, National and Kapodistrian University of Athens, Athens, Greece

Series editor: Michele Ghielmini, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Contributors

Chapter 1 - Epidemiology, Risk factors and Pathogenesis of Squamous Cell Tumours

  • P Economopoulou - Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, School of Medicine, Athens, Greece
  • A Psyrri - Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, School of Medicine, Athens, Greece

Chapter 2 - Diagnosis and Staging of Squamous Cell Tumours

  • R Mesía - Catalan Institute of Oncology, Medical Oncology Department, Head and Neck Unit, Universitat de Barcelona, Barcelona, Spain
  • M Taberna - Catalan Institute of Oncology, Medical Oncology Department, Head and Neck Unit, Universitat de Barcelona, Barcelona, Spain

Chapter 3 - Histopathological and Molecular Characterisation of Squamous Cell Tumours

  • L Martin - Unit of Oral and Maxillofacial Pathology, School of Clinical Dentistry, Sheffield Teaching Hospitals University NHS Trust, Sheffield, UK
  • KD Hunter - Unit of Oral and Maxillofacial Pathology, School of Clinical Dentistry, Sheffield Teaching Hospitals University NHS Trust, Sheffield, UK

Chapter 4 - Site- and Stage-driven Treatment Strategy in Non-metastatic Disease

  • L Licitra - Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan; Università degli Studi Milano, Milan, Italy
  • S Alfieri - Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
  • M Imbimbo - Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

Chapter 5 - Principles of Surgery of Squamous Cell Tumours

  • A Dietz - Department of Otolaryngology, Head and Neck Surgery, and Department of Head Medicine and Oral Health, University of Leipzig, Leipzig, Germany
  • S Wiegand - Department of Otolaryngology, Head and Neck Surgery, University of Leipzig, Leipzig, Germany

Chapter 6 - Principles of Radiotherapy of Squamous Cell Tumours

  • N Slevin - The Christie NHS Foundation Trust, Manchester, UK
  • LW Lee - The Christie NHS Foundation Trust, Manchester, UK

Chapter 7 - Treatment of Recurrent or Metastatic Disease

  • MV Karamouzis - Molecular Oncology Unit, Department of Biological Chemistry, First Department of Internal Medicine, Laiko Hospital Medical School, National and Kapodistrian University of Athens, Athens, Greece

Chapter 8 - Thyroid Carcinomas

  • R Elisei - Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy
  • A Matrone - Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy
  • C Romei - Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy

 Chapter 9 - Nasopharyngeal Carcinoma

  • A Chan - Partner State Key Laboratory of Oncology in South China, Department of Clinical Oncology, Sir Y.K. Pao Center for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region (SAR), China
  • SF Leung - Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong Special Administrative Region (SAR), China
  • EP Hui - Partner State Key Laboratory of Oncology in South China, Department of Clinical Oncology, Sir Y.K. Pao Center for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region (SAR), China

Chapter 10 - Salivary Gland Tumours

  • LD Locati - Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
  • M Imbimbo - Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

Chapter 11 - Individualised Supportive Care Before and During Curative Treatment of Head and Neck Tumours

  • P Bossi - Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
  • P Economopoulou - Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, School of Medicine, Athens, Greece
  • A Psyrri - Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, School of Medicine, Athens, Greece

Chapter 12 - Emerging Targets and New Agents in Squamous Head and Neck Tumours

  • E Seront - Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels; Department of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint-Paul, Belgium
  • JP Machiels - Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium

Declarations of interest

  • S Alfieri: No conflicts of interest.
  • P Bossi: No conflicts of interest.
  • A Chan: No conflicts of interest.
  • A Dietz: No conflicts of interest.
  • P Economopoulou: No conflicts of interest.
  • R Elisei: Consultant and speaker bureau for Eisai, Exelixis, Bayer, AstraZeneca, Genzyme.
  • EP Hui: No conflicts of interest.
  • KD Hunter: No conflicts of interest.
  • M Imbimbo: No conflicts of interest.
  • MV Karamouzis: No conflicts of interest. 
  • LW Lee: No conflicts of interest.
  • SF Leung: No conflicts of interest.
  • L Licitra: Consultancy/advisory boards for Bristol-Myers Squibb, MSD, Merck-Serono, Boehringer Ingelheim, Debiopharm, SOBI, Novartis, AstraZeneca, Roche; research grants from EISAI, MSD, Merck-Serono, Boehringer Ingelheim, Novartis, AstraZeneca, Roche; travel grants from Merck-Serono, Debiopharm, SOBI, Bayer.
  • LD Locati: No conflicts of interest.
  • JP Machiels: Advisor for Boerhinger-Ingelheim, Merck Sharp & Dohme; research grants from Bayer, Janssen, Novartis.
  • L Martin: No conflicts of interest.
  • A Matrone: Travel grants from Genzyme, Bayer.
  • R Mesía: Advisory boards and educational meetings as faculty and speaker for Merck Serono, Bayer, AstraZeneca; occasional travel fund from Merck Serono.
  • A Psyrri: No conflicts of interest.
  • C Romei: Consultant for Eisai; travel grants from Genzyme and Bayer.
  • E Seront: No conflicts of interest.
  • N Slevin: No conflicts of interest.
  • M Taberna: Advisory boards as speaker for Merck Serono Group.
  • S Wiegand: No conflicts of interest.

« Previous Page

Last update: 27 June 2017